Clinical Trials Directory

Before starting treatment, patients will have tests and check-ups for up to 4 weeks. Then, treatment happens in cycles that last 6 weeks. Most people will have up to six cycles. After treatment, doctors will check on patients for about 3 years with visits every 12 weeks. Some early visits may take a long time, up to 6 to 12 hours. There are different groups in the study: - Doublet group: Gets two medicines (AMO959 and AAA617). - Triplet group: Gets three medicines (AMO959, AAA617, and ARPI). - Food-effect group: Tests how food changes AMO959 levels. In each cycle, AAA617 is given on Day 1. AMO959 is taken twice a day from Day 2 to Day 15. The triplet group also takes ARPI every day. The study is open-label, which means you and the doctors know which treatment you are getting. Patients will have regular visits, blood and urine tests, heart checks (ECGs), and scans like CT, MRI, bone scans, and PSMA-PET.

We are doing this study to find out if an experimental drug called CAP-100 (study drug) is a safe and effective treatment for people who have CLL or SLL that is not responding to standard treatments. We also want to know what dose of this study drug works best.

We are doing this study to monitor the health and quality of life of people who participated in clinical trials for GM T cell therapies.

We are doing this study to find out if an experimental drug called cema-cel is a safe and effective option for patients with large B-cell lymphoma. Cema-cel is a CAR T Cell therapy that is made from your own white blood cells. We also want to compare how well cema-cel works when it is given with and without another experimental drug called ALLO-647.

In this study, people will get a medicine called CLSP-1025 through a needle in their arm. They may need to stay in the hospital for 2 days after the first two doses. They will have regular checkups, tests, and scans. The study can last up to 2 years if the medicine helps and they feel okay. Everyone in the study gets the medicine - no one gets a fake treatment.

We are doing this study to find out if neratinib combined with palbociclib is better than neratinib alone when it comes to treating HER2-positive tumors.

The study wants to learn three things: 1. How many patients with medulloblastoma can live at least 4 months without their tumor getting worse. 2. How many patients with DIPG live for 1 year after getting radiation and the PEP-CMV vaccine. 3. How many patients with HGG live for 1 year without their tumor getting worse after radiation and the PEP-CMV vaccine.